StockNews.com Initiates Coverage on Organovo (NASDAQ:ONVO)

Analysts at StockNews.com initiated coverage on shares of Organovo (NASDAQ:ONVO) in a research report issued to clients and investors on Saturday. The brokerage set a “sell” rating on the medical research company’s stock.

Organovo Price Performance

Shares of Organovo stock opened at $1.03 on Friday. The stock has a market capitalization of $10.34 million, a P/E ratio of -0.47 and a beta of 0.87. The business has a 50 day simple moving average of $1.04 and a two-hundred day simple moving average of $1.11. Organovo has a 12 month low of $0.89 and a 12 month high of $2.05.

Organovo (NASDAQ:ONVO) last posted its quarterly earnings data on Thursday, February 8th. The medical research company reported ($0.40) EPS for the quarter, beating the consensus estimate of ($0.41) by $0.01. The firm had revenue of $0.01 million during the quarter, compared to analyst estimates of $0.08 million. As a group, research analysts anticipate that Organovo will post -1.74 EPS for the current fiscal year.

Organovo Company Profile

Organovo Holdings, Inc, a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture.